Moderna Inc. (MRNA) witnessed a steep pre-market decline of 21.18% on Monday, as the biotechnology company slashed its 2025 revenue forecast, citing sluggish launch of its respiratory syncytial virus (RSV) vaccine mRESVIA and waning demand for COVID-19 vaccines.
The company now expects its 2025 revenue to range between $1.5 billion and $2.5 billion, marking a significant reduction from its previous projection of $2.5 billion to $3.5 billion. This revised forecast fell short of analysts' average estimate of $2.95 billion for the year.
The disappointing outlook reflects the challenges Moderna is facing in its transition from its pandemic-driven success with COVID-19 vaccines. As the demand for these shots wanes, the company's newly launched RSV vaccine, mRESVIA, has also faced a lackluster reception, with negligible sales reported.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.